NOVA HEALTH PEPTIDES LLC ARIEL GUTIERREZ SOLE MBR Review: Consulted Sources Do Not Confirm a GLP-1 Program

01Start with the business the documents actually describe

The separate terms name NOVA HEALTH PEPTIDES LLC ARIEL GUTIERREZ SOLE MBR as the site's owner and operator. That is the visible business identity used here. Although the website address is slimshot.net, its domain does not by itself establish “Slimshot” as a declared trading name. In fact, the ownership sentence includes an empty d/b/a field. Readers should distinguish a memorable web address from the entity identified as responsible for the site and its terms.

The clinical pages advertise medical weight-loss care delivered by a licensed physician. They also say professional credentials are available through the entity. These are provider statements, not independently verified licensing findings. The consulted documentation does not identify the treating physician by name, provide license numbers, establish board certification or name a separate clinical entity. Requesting those details would help connect the advertised professional role to the person who would actually conduct a consultation.

Most importantly, no named medicine, active ingredient, administration route or compounded preparation is identified. Neither the business name nor the weight-management framing fills that gap. The absence of a documented GLP-1 offering is not proof that no such service exists; it is a limit on what this review can verify. Our guide to what public provider documents can prove explains why an operator's identity, advertised services and clinical evidence require separate checks.

02What an initial evaluation is advertised to cover

The advertised entry point is a consultation about health history, previous weight-loss attempts and clinical goals. Elsewhere, the practice says the physician reviews relevant medical history, lifestyle factors and metabolic health considerations. Together, these statements outline a discussion-based evaluation rather than an automatic prescription transaction. They do not establish the appointment's length, whether records must be submitted beforehand or whether a separate assessment occurs before a clinician sees the patient.

The practice also advertises “Metabolic Health Assessments,” described as reviewing factors that can influence weight, energy, appetite and long-term health outcomes. That description does not specify laboratory panels, physical measurements or diagnostic testing. It would therefore be inaccurate to present bloodwork or a particular metabolic test as an included service. A useful clarification is whether the assessment is primarily a history review, involves testing, or requires results obtained elsewhere—and who pays for any additional work.

Care recommendations are described as individualized around needs, health status and sustainable routines. The potential plan components include medical guidance, nutrition education and lifestyle support. The wording matters: a plan “may include” those elements, which is different from a guaranteed package with a fixed list of included appointments. The pages support a description of the practice's intended approach, but not a detailed service specification or evidence that every patient receives every advertised component.

03Eligibility and telehealth are conditional, not guaranteed

The practice says candidacy depends on medical history, current health, goals and the physician's clinical assessment. Its separate terms require users enrolling in programs to be at least 18 and legally capable of entering a binding agreement. Those terms also state that services are not intended for minors, people who are pregnant or breastfeeding, or people with certain contraindicated medical conditions. The relevant passage does not enumerate those conditions, so it cannot serve as a complete screening checklist.

Telehealth is offered conditionally: appointments may be available for eligible patients when clinically appropriate and allowed by applicable regulations. This is not a promise of nationwide access or of remote care for every applicant. Although the footer mentions Sarasota, Florida, the consulted documentation does not establish a consultation address or a list of supported states and territories. A Florida reference alone cannot tell an out-of-state reader whether the practice can provide care where that reader is located.

Before arranging an appointment, a prospective patient can ask whether the practice serves their location, who would conduct the visit and whether any part of the evaluation must occur in person. The website does not publish BMI thresholds or a complete list of required tests. That missing detail should not be replaced with criteria borrowed from another clinic or a medicine's general eligibility framework. The relevant evidence is this practice's actual screening process, explained by the clinician responsible for care.

04Follow-up is described, but its practical scope remains open

The practice advertises professional guidance around food, activity, sleep and daily routines. It also describes follow-up visits as opportunities to evaluate progress and adjust the plan when clinically appropriate. These are meaningful service descriptions, but they are not a published schedule. The documentation says follow-up frequency varies by patient and that the physician recommends a monitoring cadence based on the plan, progress and clinical needs. There is no fixed weekly or monthly visit entitlement established here.

That flexibility could allow different care plans, but the public description does not reveal how access works between appointments. No confirmed patient portal, clinical messaging timetable or named backup clinician is established in the consulted pages. Readers should ask how questions about an existing plan are routed, whether another appointment is required and what happens when the usual clinician is unavailable. Those questions concern the delivery of the advertised service, not an assumption that a particular medicine will be prescribed.

Clinical follow-up should also be distinguished from administrative support. The terms explicitly say customer support is not a substitute for emergency medical services. More broadly, NIDDK describes medication follow-up as involving response and tolerability, not simply continued payment. That is relevant context if medication is later discussed, not confirmation of a medication program here. Our guide to clinical follow-up explains why a useful monitoring description should identify responsibilities as well as appointment frequency.

05The evidence needed to move beyond a service description

The central evidence gap is not a missing weight-loss percentage. It is the absence of an identified treatment offering to evaluate. The consulted documentation does not establish a medication, formulation, pharmacy or prescribing pathway. Published drug-trial findings therefore cannot be attached to this practice as its expected results. Nor does a statement about individualized care establish treatment effectiveness. A documented consultation process and demonstrated clinical outcomes are different kinds of evidence, and this website primarily supplies the former.

If the practice later identifies a medication option, the next questions would concern the exact product, its route, whether it is FDA approved or compounded, and who prescribes and dispenses it. FDA approval applies to a specific product, not to a clinic or pharmacy. FDA says compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. That distinction alone does not prove clinical inequivalence or establish a judgment about this business.

FDA recommends compounded drugs when an individual's medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nothing in the consulted provider pages establishes that this practice offers compounded treatment. These are questions to apply only if such an option is actually proposed. Our guides on trial results versus provider performance and approved versus compounded preparations explain the evidence boundaries without assigning an undocumented treatment to the practice.

06Prices, purchase terms and refunds need a specific written offer

The consulted pages do not establish consultation charges, program prices, medication fees, discounts or included financial benefits. They also do not establish insurance acceptance, insurer billing or out-of-network reimbursement. Consequently, there is no defensible first-payment figure or monthly comparison to report. The appropriate next document would be a written offer specifying the service, its price and what is included, rather than an estimate inferred from other weight-management businesses.

General terms say a purchase may or may not qualify for a refund and that each product, service, event or course has its own policy. That language does not establish a medical-program refund entitlement. The terms also contemplate additional conditions for products or services purchased through the site, without identifying a pharmacy partner. No specific medical-care renewal rule, recurring billing schedule, cancellation deadline or minimum commitment is established. Ending text messages cannot be treated as ending a financial agreement.

The table below separates several decisions that the public documentation leaves unresolved. These are not findings that the practice imposes undisclosed charges; they are the details needed to understand an actual offer before accepting it. Because the general terms range across services, products, courses and events, a program-specific written explanation would be more useful than relying on those broad provisions to predict the cost or refund consequences of medical care.

07Contact, account access and text-message consent

The practice invites prospective patients to contact it by phone or email about consultation availability and next steps. The published telephone number is +1 941-250-4470. In the consulted material, the email address is obscured rather than available as a usable address. Concrete support hours are not established. The separate terms' response-time sentence retains the example placeholder “[e.g., 24–48] business hours,” so it should not be treated as a completed response-time commitment.

Account support is limited to the registered account holder. The terms say discussions with third parties, including spouses or friends, require a legal basis or a signed HIPAA release. They also state that profanity, hate speech or personal attacks will end a support session and may lead to permanent account or service suspension without a refund. These are material service conditions, especially for someone expecting a family member to handle billing questions or communicate on their behalf.

The homepage says SMS notifications can be stopped by replying STOP, with opt-out requests processed within 24 hours. That is a messaging timeframe, not a clinical response or treatment-cancellation timeframe. The separate privacy policy describes opt-in consent covering operational and promotional texts, while the homepage says promotional content requires specific consent. The policy also says mobile information and SMS opt-in data will not be shared for third-party or affiliate marketing, and permits requests to access, correct, update or delete submitted personal information.

08Unfinished legal language limits confidence in the paperwork

Several inconsistencies go beyond a missing fee schedule. The separate terms refer to the “State of United Kingdom” and place arbitration in “United States, United States.” The homepage terms instead connect arbitration to the jurisdiction of the state where the entity operates. These passages do not provide a clear, consistent account of the governing framework. This review does not determine legal enforceability; the practical issue is that a reader cannot readily reconcile the versions.

Other template remnants include “Your Agency Name,” the blank d/b/a field and a date containing “{{right_now.year}}.” The separate terms also declare an exclusively educational purpose and include investment-related references, despite other pages describing medical consultations and treatment. References to courses and events further broaden the mismatch. None of these passages should automatically be converted into a specific restriction on medical care, but collectively they make it harder to identify which provisions were deliberately written for this practice.

The most useful response is to request the current, complete documents that apply to the proposed medical service: the responsible clinical entity, clinician details, consent documents, financial agreement and cancellation and refund policy. Clarification should also resolve which SMS consent is requested and which terms govern enrollment. A corrected document would not by itself prove clinical quality, but it would improve the ability to understand responsibilities before entering care. Public-facing paperwork is evidence of stated obligations, not a substitute for a verified clinical relationship.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Wilding et al. (2021): STEP 1 semaglutide trial ↗
4. Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
5. NOVA HEALTH PEPTIDES LLC ARIEL GUTIERREZ SOLE MBR — official website ↗
6. NOVA HEALTH PEPTIDES LLC ARIEL GUTIERREZ SOLE MBR — privacy policy 447254 ↗
7. NOVA HEALTH PEPTIDES LLC ARIEL GUTIERREZ SOLE MBR — terms of service 653678 ↗

Continue reading

• What Public GLP-1 Provider Documents Can—and Cannot—Prove
• A Clinical Trial Is Not a Telehealth Company Performance Report
• FDA-Approved Medicines and Compounded Preparations: Separate Evidence Questions
• Follow-up Is a Clinical Question, Not Just a Renewal Notice
• A Reader’s Checklist for GLP-1 Medical Claims